SubHero Banner
Text

March 2024

Core topics in this month’s edition include:

  • Jubbonti (denosumab-bbdz) – new first-time interchangeable biosimilar approval
  • Rezdiffra (resmetirom) – new drug approval
  • Wegovy (semaglutide) – new indication
  • Wyost (denosumab-bbdz) – new first-time interchangeable biosimilar approval

Download PDF

Text